Secondary hyperparathyroidism (HPT) in patients receiving peritoneal dialysis (PD) can be effectively managed with cinacalcet (MIMPARA®/SENSIPAR®)

被引：0
|
作者：
Gonzalez, M. T.
Hutchison, A. J.
Girndt, M.
Stahl-Nilsson, A.
Zani, V.
Carter, D.
Molemans, B.
Bos, W. J. W.
机构：
[1] Hosp Univ Bellvitge, Barcelona, Spain
[2] Mission Res Inc, Manchester, Lancs, England
[3] Univ Saarlandes Kliniken, Homburg, Germany
[4] Lanssjukhuset Ryhov, Jonkoping, Sweden
[5] Amgen Inc, Zug, Switzerland
[6] St Antonius Hosp, Nieuwegein, Netherlands
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2006年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
引用
收藏
页码：134 / 134
页数：1
相关论文
共 50 条
  • [1] Cinacalcet (MIMPARA®/SENSIPAR®) maintains achievement of NKF-K/DOQI treatment targets for secondary hyperparathyroidism (HPT) in patients on dialysis
    Frazao, JM
    Holzer, H
    Stummvoll, HK
    Bahner, U
    Wilkie, M
    Zani, V
    Hutton, H
    Motellon, JL
    Braun, J
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V89 - V89
  • [2] Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism
    Sterrett, J. R.
    Strom, J.
    Stummvoll, H-K
    Bahner, U.
    Disney, A.
    Soroka, S. D.
    Corpier, C.
    Arruda, J. A.
    Schwanauer, L. E.
    Klassen, P. S.
    Olson, K. A.
    Block, G. A.
    CLINICAL NEPHROLOGY, 2007, 68 (01) : 10 - 17
  • [3] Cinacalcet (Mimpara®/Sensipar®) effectively reduces intact parathyroid hormone (iPTH) and serum calcium (Ca) regardless of serum calcium level in patients with secondary hyperparathyroidism (HPT)
    De Francisco, A
    Evenepoel, P
    Brink, HS
    Mellotte, G
    Barata, JD
    Zani, V
    Hutton, S
    Klassen, P
    Ritz, E
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V197 - V198
  • [4] The OPTIMA study:: Assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism
    Messa, Piergiorgio
    Macario, Fernando
    Yaqoob, Magdi
    Bouman, Koen
    Braun, Johann
    von Albertini, Beat
    Brink, Hans
    Maduell, Francisco
    Graf, Helmut
    Frazao, Joao M.
    Bos, Willem Jan
    Torregrosa, Vicente
    Saha, Heikki
    Reichel, Helmut
    Wilkie, Martin
    Zani, Valter J.
    Molemans, Bart
    Carter, Dave
    Locatelli, Francesco
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (01): : 36 - 45
  • [5] Sensipar® (cinacalcet HCI) reduces PTH levels in dialysis patients with severe secondary HPT
    Block, GA
    Coco, M
    Abu-Alfa, AK
    Bradley, CR
    LaBrecque, JF
    Turner, SA
    Corpier, CL
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (04) : A20 - A20
  • [6] The effect of cinacalcet(Mimpara®/Sensipar®) on the achievement of KDOQI™ treatment targets by severity of secondary hyperparathyroidism (SHPT)
    Zitt, Emanuel
    Saha, Heiki
    Os, Ingrid
    Leavey, Sean
    Ryba, Miroslav
    Banos, Ana
    Harris, Chris
    Zani, Wal
    Bencova, Veronika
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 215 - 215
  • [7] The optima study:: Lower doses of cinacalcet (Mimpara®/Sensipar®) are required to achieve KDOQI™ secondary hyperparathroidism (HPT) targets in dialysis patients with less severe disease
    Messa, P.
    Villa, G.
    Braun, J.
    Maduell, F.
    Cruz, J.
    Martin, P. Y.
    Kovarik, J.
    Saha, H.
    Zani, V.
    Carter, D.
    Molemans, B.
    Frazao, J.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 407 - 407
  • [8] The Optima study:: Earlier intervention of Cinacalcet HCl (Sensipar®/Mimpara®) enables greater achievement of KDOQI™ secondary hyperparathyroidism (SHPT) targets in dialysis patients.
    Frazao, JM
    Macário, F
    Yaqoob, M
    Bouman, K
    Braun, J
    von Albertini, B
    Brink, HS
    Maduell, F
    Graf, H
    Saha, H
    Zani, V
    Carter, D
    Molemans, B
    Messa, P
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (04) : A30 - A30
  • [9] Phase 3 experience with cinacalcet HCl in hemodialysis (HD) and peritoneal dialysis (PD) patients with secondary HPT.
    Lindberg, JS
    Culleton, B
    Wong, G
    Borah, MF
    Clark, RV
    Shapiro, WB
    Roger, SD
    Husserl, FE
    Klassen, PS
    Guo, MD
    Albizem, MB
    Coburn, JW
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 463A - 463A
  • [10] A population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of cinacalcet HCl in renal-dialysis patients with secondary hyperparathyroidism (HPT).
    Wang, B
    Ludden, T
    Gonzalez, M
    Rein, P
    Harris, R
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P62 - P62
12345